The stock of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) has decreased by -0.12 when compared to last closing price of 0.59. Despite this, the company has experienced a -5.17% fall in its stock price over the last five trading sessions. newsfilecorp.com reported 2024-12-02 that Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom–(Newsfile Corp. – December 2, 2024) – Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA® (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults.
Is It Worth Investing in Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Right Now?
Company’s 36-month beta value is 2.18.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ADAP is 226.49M, and currently, short sellers hold a 2.97% ratio of that floaft. The average trading volume of ADAP on December 17, 2024 was 1.72M shares.
ADAP’s Market Performance
The stock of Adaptimmune Therapeutics Plc ADR (ADAP) has seen a -5.17% decrease in the past week, with a 0.70% rise in the past month, and a -43.20% fall in the past quarter. The volatility ratio for the week is 7.22%, and the volatility levels for the past 30 days are at 8.20% for ADAP. The simple moving average for the last 20 days is -10.44% for ADAP stock, with a simple moving average of -43.87% for the last 200 days.
Analysts’ Opinion of ADAP
Many brokerage firms have already submitted their reports for ADAP stocks, with H.C. Wainwright repeating the rating for ADAP by listing it as a “Buy.” The predicted price for ADAP in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on July 30, 2024 of the current year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see ADAP reach a price target of $3.15. The rating they have provided for ADAP stocks is “Sector Outperform” according to the report published on May 30th, 2024.
Bryan Garnier gave a rating of “Buy” to ADAP, setting the target price at $3.60 in the report published on March 24th of the previous year.
ADAP Trading at -19.84% from the 50-Day Moving Average
After a stumble in the market that brought ADAP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.18% of loss for the given period.
Volatility was left at 8.20%, however, over the last 30 days, the volatility rate increased by 7.22%, as shares surge +0.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.57% lower at present.
During the last 5 trading sessions, ADAP fell by -4.41%, which changed the moving average for the period of 200-days by -59.77% in comparison to the 20-day moving average, which settled at $0.6598. In addition, Adaptimmune Therapeutics Plc ADR saw -25.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADAP starting from Piccina Cintia, who sale 24,531 shares at the price of $0.93 back on Jun 18 ’24. After this action, Piccina Cintia now owns 38,293 shares of Adaptimmune Therapeutics Plc ADR, valued at $22,814 using the latest closing price.
Rawcliffe Adrian, the Chief Executive Officer of Adaptimmune Therapeutics Plc ADR, sale 30,080 shares at $0.67 during a trade that took place back on Jan 17 ’24, which means that Rawcliffe Adrian is holding 44,848 shares at $20,244 based on the most recent closing price.
Stock Fundamentals for ADAP
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.95 for the gross margin
The net margin for Adaptimmune Therapeutics Plc ADR stands at -0.26. The total capital return value is set at -0.19. Equity return is now at value -53.54, with -14.66 for asset returns.
Based on Adaptimmune Therapeutics Plc ADR (ADAP), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -2.62. The debt to equity ratio resting at 0.26. The interest coverage ratio of the stock is -30.04.
Currently, EBITDA for the company is -128.2 million with net debt to EBITDA at 2.42. When we switch over and look at the enterprise to sales, we see a ratio of 0.34. The receivables turnover for the company is 4.53for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.85.
Conclusion
In a nutshell, Adaptimmune Therapeutics Plc ADR (ADAP) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
